pharma · Asthma · Multiple Sclerosis · TEVA
Teva Pharma
Teva Pharma GmbH
Teva Biotech is a pharma organization headquartered in TEL AVIV, DE. It trades on NYSE under ticker TEVA. Primary therapeutic focus areas include Asthma, Multiple Sclerosis, Pain, Crohn's Disease, Seasonal Allergic Rhini
Company details
- Status
- Public
- HQ
- 10 Dornierstr., Ulm, Donau, 89079, DE, TEL AVIV
- Employees
- 126
- Programs
- 473
- Drugs
- 447
- Patents
- 454
Quick answer
Teva Biotech is a pharma organization headquartered in TEL AVIV, DE. It trades on NYSE under ticker TEVA. Primary therapeutic focus areas include Asthma, Multiple Sclerosis, Pain, Crohn's Disease, Seasonal Allergic Rhinitis. NovaPharmaNews links 473 clinical program(s), 215 drug profile(s), and 454 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 1 (154), phase 3 (148), phase 2 (126).
Company snapshot
Teva Pharma maintains 473 tracked programs across Asthma, Multiple Sclerosis, Pain, Crohn's Disease, Seasonal Allergic Rhinitis, Pharmacokinetics, Multiple Myeloma, Relapsing Remitting Multiple Sclerosis, Cancer, Contraception, Acute Myeloid Leukemia, Parkinson's Disease. Momentum score: 32/100 (30-day delta: n/a). Public registry data covers pipeline phase, clinical trials, patents, SEC filings,
- 243 approved product(s) across US/EU regulatory metadata.
- 473 active pipeline program(s) linked via ClinicalTrials.gov.
- 454 US patent(s) indexed to this assignee profile.
Public regulatory, clinical, patent, and corporate records for Teva Pharma. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- approval
Teva's Once-Monthly Schizophrenia Shot Enters EMA Review, Signaling New Treatment Option
- approval
Teva's Olan EMA Application Acceptance: Strategic Implications for Pharma
Recent coverage
Teva's Olan EMA Application Acceptance: Strategic Implications for Pharma
Teva Pharmaceuticals has received acceptance from the European Medicines Agency (EMA) for its marketing authorization application for Olan. This pivotal regulatory step signals a deeper review process and potential market entry, with significant implications for the pharmaceutical industry.
Teva's Once-Monthly Schizophrenia Shot Enters EMA Review, Signaling New Treatment Option
The European Medicines Agency (EMA) has accepted Teva Pharmaceuticals and Medincell's marketing authorization application for their once-monthly olanzapine long-acting injectable (LAI) for the treatment of schizophrenia in adults. This regulatory milestone signifies a potential new adherence-focused treatment option for patients in Europe.
Top assets
Lead pipeline drugs
- approved
- approved
- approved
- approved
Active clinical programs
- Phase 3
- Phase 3
- Phase 3
- Phase 3
Congress & presentations
- PresentationPhase III Data: Teva's Ajovy (fremanezumab) in Migraine Prevention
- CongressIMPHARMA2026
Momentum
Proprietary activity score for Teva Pharma.
3 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitor landscape
Therapeutic-area overlap peers from registry and pipeline signals.
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
Recent activity
Latest pipeline, patent, and corporate events for Teva Pharma.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is Teva Pharma?
-
Is Teva Pharma publicly traded?
-
What drugs does Teva Pharma develop or market?
-
What are the latest developments for Teva Pharma?
-
What therapeutic areas does Teva Pharma focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.